Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen Announces Publication of the Company's 2022 Sustainability Report
07:30am, Tuesday, 14'th Nov 2023
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
Repligen Corporation to Present at Upcoming Investor Conferences
07:30am, Tuesday, 07'th Nov 2023
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates
10:32am, Tuesday, 31'st Oct 2023
Repligen (RGEN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.77 per share a year ago.
Repligen to Report Third Quarter 2023 Financial Results
07:30am, Tuesday, 17'th Oct 2023
Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET
Repligen (RGEN) to Acquire Fluid Management Company Metenova
08:16am, Wednesday, 27'th Sep 2023
Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.
Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report?
12:49pm, Friday, 01'st Sep 2023
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation to Present at Wells Fargo Healthcare Conference
07:30am, Friday, 01'st Sep 2023
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presentin
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
12:45pm, Thursday, 03'rd Aug 2023
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript
03:26pm, Wednesday, 02'nd Aug 2023
Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Ex
Repligen (RGEN) Q2 Earnings Surpass Estimates
10:27am, Wednesday, 02'nd Aug 2023
Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.91 per share a year ago.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
01:08pm, Tuesday, 25'th Jul 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi
Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing
11:35am, Tuesday, 18'th Jul 2023
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use produ
Repligen Corporation: Not Able To Replicate The Strong Results
12:11pm, Monday, 05'th Jun 2023
Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
02:27pm, Wednesday, 03'rd May 2023
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
10:40am, Tuesday, 02'nd May 2023
Repligen (RGEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.92 per share a year ago.
